ID(H)entifying checkpoint inhibitor candidates among diffuse glioma

Affiliations

¹ Department of Neuropathology, University Hospital Heidelberg and Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany; Neurology Clinic, University Hospital Heidelberg and Clinical Cooperation Unit Neurooncology, German Consortium for Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany.

Comment

Felix Sahm et al. Neuro Oncol. 2017.

. 2017 Oct 19;19(11):1427-1428.

doi: 10.1093/neuonc/nox145.

¹ Department of Neuropathology, University Hospital Heidelberg and Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany; Neurology Clinic, University Hospital Heidelberg and Clinical Cooperation Unit Neurooncology, German Consortium for Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany.

No abstract available

Comment on

Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M. Berghoff AS, et al. Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054. Neuro Oncol. 2017. PMID: 28531337 Free PMC article.

1. Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol. 2016;17(12):e529–e541. - PubMed
1. Nduom EK, Wei J, Yaghi NK et al. . PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18(2):195–205. - PMC - PubMed
1. Berghoff AS, Kiesel B, Widhalm G et al. . Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17(8):1064–1075. - PMC - PubMed
1. Garber ST, Hashimoto Y, Weathers SP et al. . Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016;18(10):1357–1366. - PMC - PubMed
1. Reardon DA, Gokhale PC, Klein SR et al. . Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res. 2016;4(2):124–135. - PubMed